10:43 AM EST - Resverlogix Corp. : Announced today the publishing of an article titled: "Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro", in Biomedicines, a high-impact scientific journal. The previously announced findings , made in collaboration with Dr. Dalia ElGamal’s research group at the University of Nebraska Medical Center (UNMC), Omaha, Nebraska, have completed the peer-review process. Resverlogix Corp.
shares T.RVX are trading up $0.02 at $0.89.
